Time to benefit is the time between the intervention (usually a test or treatment) and its benefit.
The following figure shows which preventive treatments your patient may benefit from and which may be harmful based on your patient’s life expectancy and the time to benefit for each intervention.
Adjust life expectancy using the orange slider.
Generally not recommended
Rationalizing prescribing for older patients with multimorbidity: considering time to benefit.
Holmes HM, Min LC, Yee M, Varadhan R, Basran J, Dale W, Boyd CM.
Drugs Aging. 2013 Sep;30(9):655-66. doi: 10.1007/s40266-013-0095-7. Review.
Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians
Amir Qaseem, Timothy J. Wilt, Robert Rich, Linda L. Humphrey, Jennifer Frost, and Mary Ann Forciea
Annals of Internal Medicine 2017 166:6, 430-437
Yourman LC, Cenzer IS, Boscardin WJ, et al. Evaluation of Time to Benefit of Statins for the Primary Prevention of Cardiovascular Events in Adults Aged 50 to 75 Years: A Meta-analysis. JAMA Intern Med. 2021;181(2):179–185. doi:10.1001/jamainternmed.2020.6084
Chen T, Shao F, Chen K, et al. Time to Clinical Benefit of Intensive Blood Pressure Lowering in Patients 60 Years and Older With Hypertension: A Secondary Analysis of Randomized Clinical Trials. JAMA Intern Med. Published online May 09, 2022. doi:10.1001/jamainternmed.2022.1657
Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992 Oct 22;327(17):1185-91. doi: 10.1056/NEJM199210223271701. PMID: 1383816.
King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol.
Estimating the Time to Benefit for Preventive Drugs with the Statistical Process Control Method: An Example with Alendronate. van de Glind EM, Willems HC, Eslami S, et al. Drugs Aging. 2016;33(5):347-353. doi:10.1007/s40266-016-0344-7
Deardorff WJ, Cenzer I, Nguyen B, Lee SJ. Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. Published online November 22, 2021. doi:10.1001/jamainternmed.2021.6745
Time lag to benefit after screening for breast and colorectal cancer: meta-analysis of survival data from the United States, Sweden, United Kingdom, and Denmark.
Lee SJ, Boscardin WJ, Stijacic-Cenzer I, Conell-Price J, O'Brien S, Walter LC.
BMJ. 2013 Jan 8;346:e8441. doi: 10.1136/bmj.e8441. PMID: 23299842
Time to benefit for colorectal cancer screening: survival meta-analysis of flexible sigmoidoscopy trials.
Tang V, Boscardin WJ, Stijacic-Cenzer I, Lee SJ.
BMJ. 2015 Apr 16;350:h1662. doi: 10.1136/bmj.h1662. Erratum in: BMJ. 2015;350:h2228.
Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults: A Guidance Statement From the American College of Physicians (ACP)
Amir Qaseem, Carolyn J. Crandall, Reem A. Mustafa, Lauri A. Hicks, and Timothy J. Wilt
Annals of Internal Medicine 2019 171:9, 643-654
Screening for Breast Cancer in Average-Risk Women: A Guidance Statement From the American College of Physicians (ACP)
Amir Qaseem, Jennifer S. Lin, Reem A. Mustafa, Carrie A. Horwitch, and Timothy J. Wilt
Annals of Internal Medicine 2019 170:8, 547-560
Freedman RA, Minami CA, Winer EP, et al. Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer: Multidisciplinary Expert Panel and International Society of Geriatric Oncology Consensus Statement. JAMA Oncol. Published online January 28, 2021.
The information provided on ePrognosis is designed to complement, not replace, the relationship between a patient and his/her own medical providers. ePrognosis was created with the support of the Division of Geriatrics at the University of California San Francisco. However, its content is strictly the work of its authors and has no affiliation with any organization or institution. This web site does not accept advertisements. If you reproduce the material on the website please cite appropriately. For feedback and questions regarding the site please email Sei Lee, MD (firstname.lastname@example.org), Alex Smith, MD (email@example.com) or Eric Widera, MD (firstname.lastname@example.org).